How to Buy Bridgebio Pharma Stock
Bridgebio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
Bridgebio Pharma stock last closed at $62.64, down 1.15% from the previous day, and has increased 167.58% in one year. It has overperformed other stocks in the Biotechnology industry by 1.88 percentage points. Bridgebio Pharma stock is currently +188.4% from its 52-week low of $21.72, and -9.84% from its 52-week high of $69.48.
There are currently 192.71M shares of BBIO outstanding. The market value of BBIO is $12.07B. In the last 24 hours, 2.47M BBIO shares were traded.
How to Buy Bridgebio Pharma Stock
Wondering how to invest in Bridgebio Pharma stock? Here's how.
- Decide where to buy Bridgebio Pharma stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Bridgebio Pharma stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your details.
- Analyze Bridgebio Pharma stock: The Bridgebio Pharma ticker symbol is BBIO. Is Bridgebio Pharma stock a good investment? Should you buy shares of BBIO? How do BBIO's underlying business fundamentals look? Do top analysts think Bridgebio Pharma is a good buy? Why has BBIO's stock price moved recently? (Hint: Our stock market research website can help you figure out if BBIO is a good stock to buy).
- Place your BBIO purchase: Decide if you will purchase BBIO shares at the current market price or use a limit order to buy BBIO shares at a specific price.
- Track your BBIO investment: Create a watchlist to the latest updates on your investment in Bridgebio Pharma stock.
Step 1: Decide where to buy Bridgebio Pharma stock
You need a brokerage account to access the NASDAQ market and buy BBIO stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal info so you can invest in BBIO today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create a new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've opened your account on apps for stock market, you need to deposit funds:
Check out the tutorial below if you need help depositing funds into your brokerage account.
Step 4: Analyze Bridgebio Pharma stock
Once you have identified the best place to buy Bridgebio Pharma stock, it's absolutely critical to research their stock prior to investing, so you can wrap your head around the risk and opportunity.
Bridgebio Pharma quick stats
BBIO Overview
WallStreetZen was designed to help average investors do more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on BBIO's stock page.
How is BBIO stock valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge BBIO's true value.
You can do additional valuation research on BBIO's stock here.
BBIO Financials at a glance
Positive Financial Indicators:
- BBIO has cash burn of 585927000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the BBIO balance sheet.
Negative Financial Indicators:
- BBIO has $645.94M in cash and short term investments. This is not enough to cover its annual cash burn of $585.93M.
- Total BBIO debt is still negative.
- There are more long-term liabilities than short-term assets on the BBIO balance sheet.
- BBIO profit margin has gone down from -201.5% to -225.3% in the past year.
- BBIO debt to equity ratio of -1.51 is negative.
Is it a good time to buy BBIO stock, according to Wall Street analysts?
Out of 16 Equities analysts who monitor BBIO, the consensus analyst rating on BBIO is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest BBIO Analyst Upgrades/Downgrades
Danielle Brill, a top 14% analyst from Truist Securities reiterates BBIO with a strong buy rating and raises their BBIO price target from $66.00 to $80.00, on Oct 30, 2025.
Truist Securities's Danielle Brill raised their price target on Bridgebio Pharma (NASDAQ: BBIO) by 21.2% from $66 to $80 on 2025/10/30. The analyst reiterated their Strong Buy rating on the stock.
Bridgebio Pharma reported its Q3 2025 earnings.
Brill said they revised their model to account for:
- Results of Attruby in Q3.
- Positive Phase 3 data in ribitol in LGMD2I/R9
- Positive Phase 3 results in encaleret in ADH1.
Earnings Report
For Q3 2025, Bridgebio Pharma reported:
- Loss per share of $0.95, which missed the Zacks Consensus Estimate of $(0.88) and, by 10.5%, Q3 2024’s $(0.86).
- Revenue of $120.7M, which beat the Zacks Consensus Estimate by 14.44% and Q3 2024’s $2.73M.
Management did not provide EPS and revenue guidance.
CEO Matt Outten commented: “Attruby’s first year on the market has been remarkable, with continued growth across all market segments and strong physician adoption that reflects both the differentiated clinical profile and the trust we’re earning within the community.
“We’re seeing meaningful momentum where prescribers are not only initiating more patients on therapy but continuing treatment, underscoring Attruby’s real-world impact.
“Importantly, this launch has also given us an invaluable blueprint for how we bring best-in-class medicines to patients with genetic diseases.
“With the promising results seen in BBP-418 for LGMD2I/R9 and encaleret for ADH1, we are building on a proven commercial foundation to ensure these communities, each living with urgent, unmet needs, have timely access to transformative therapies and we will apply the playbook we’ve developed to prepare for our next potential approvals.”
Raghuram Selvaraju, a top 1% analyst from HC Wainwright & Co. maintains BBIO with a buy rating and raises their BBIO price target from $80.00 to $90.00, on Oct 29, 2025.
Eliana Merle, a top 16% analyst from UBS maintains BBIO with a strong buy rating and raises their BBIO price target from $72.00 to $82.00, on Sep 12, 2025.
Anupam Rama, a top 16% analyst from JP Morgan maintains BBIO with a strong buy rating and raises their BBIO price target from $55.00 to $70.00, on Sep 3, 2025.
Greg Harrison, a top 6% analyst from ScotiaBank maintains BBIO with a buy rating and raises their BBIO price target from $55.00 to $57.00, on Aug 6, 2025.
You can dig deeper into what analysts are forecasting on the Bridgebio Pharma stock forecast page.
BBIO Trading Indicators
BBIO Growth Numbers
Last year, BBIO revenue was $353.78M. Over the last five year, BBIO's revenue has grown by 74.37% per year. This was faster than the Biotechnology industry average of 68.21%.
Dive into BBIO's earnings and revenue performance here.
Latest Insiders Trades at BBIO
Over the past 12 months, insiders at BBIO have sold more shares than they have bought.
Frank McCormick, Director of BBIO, was the latest BBIO insider to sell. They sold $7,317,270.38 worth of BBIO stock on Oct 29, 2025.
Dig into more about who owns BBIO shares here.
Can I get consistent income from BBIO stock?
No, Bridgebio Pharma doesn't provide an income stream by paying out dividends.
What others are saying about BBIO
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your BBIO purchase
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more info about buying stocks on eToro, watch the helpful video below:
Step 6: Track your BBIO investment
Now that you own some shares in BBIO, you'll want to keep up with your shares.
Make a watchlist to get notified of important updates regarding your BBIO stock.
BBIO Feed
How to Buy Stock in Bridgebio Pharma
To summarize, here are the 6 steps to buy Bridgebio Pharma stock:
- Decide where to buy Bridgebio Pharma stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Analyze Bridgebio Pharma stock
- Place your BBIO purchase
- Track your BBIO investment
If you need a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep track of your investment in Bridgebio Pharma, hit the button below to create your watchlist.
Other Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.